BioSpace News Archive

Alcyon Health LLC’s line of premium, research-based fertility supplements for uncompromising, uncomplicated nutrition to aid in the family planning process is coming soon to health and wellness e-commerce site RevNutrition.com.

WallStEquities.com strives to bring the best free research to the investment community is offering reports on PTCT, REGN, RTTR, and SGMO which can be accessed for free by signing up to www.wallstequities.com/registration.

Crime stats show that, while arrests involving alcohol are decreasing, those involving marijuana and other drugs are on the rise.

Additions to Support Growth in NARCAN® (naloxone HCI) Nasal Spray Distribution and Advance R&D Pipeline of Five Addiction Focused Programs

Intec Pharma Ltd. (NASDAQ: NTEC), a clinical-stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill(TM) platform technology, today announced that the Company’s officers will provide a corporate overview at four investor presentations in March 2018.

Smart, secure platform leverages the power of Wi-Fi to deliver safe, continuous patient monitoring in the hospital setting.

Chilmark Research’s Population Health Management Market Trends Report shows that the market for PHM solutions is not one-size-fits-all.

Celgene Corporation (NASDAQ:CELG) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Juno Therapeutics, Inc. at a price of $87.00 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 12:00 midnight ET, at the end of the day on Friday, March 2, 2018.

Smart, safe and secure diagnostic platform designed to protect patients, improve clinical care, and enhance workflow.

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, developing targeted cancer therapeutics, today announced that the initial patient successfully completed the first cycle 1 of treatment in its Phase 1b/2 multicenter trial of PCM-075 in combination with low-dose cytarabine (LDAC) in patients with Acute Myeloid Leukemia (AML).